ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK) HKSE
Currency In HKD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In HKD
| Market Cap | 2.16B |
| Enterprise Value | 1.71B |
| P/E Ratio | -6.33 |
| PEG Ratio | -0.15 |
| Price/Sales Ratio | 8.91 |
| Price/Book Ratio | 1.8 |
| Enterprise/Revenue | 6.06 |
| Enterprise/EBITDA | -4.69 |
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | December 31, 2025 |
| Profit Margin | -1.37 |
| Operating Margin | -1.36 |
| Return On Assets | -0.2 |
| Return On Equity | -0.33 |
| Revenue | 150.3M |
| Revenue/Share | 0.37 |
| Gross Profit | 134.99M |
| EBITDA | -203.03M |
| Net Income | -212.92M |
| Diluted EPS | -0.51 |
| Total Cash | 1.02B |
| Total Cash/Share | 2.39 |
| Total Debt | 228.12M |
| Total Debt/Equity | 0.29 |
| Current Ratio | 3.83 |
| Book Value Per Share | 1.86 |
| 52-Week Change | -68.91 |
| 52-Week High | 16.8 |
| 52-Week Low | 2.8 |
| Moving Average 50 Days | 4.13 |
| Moving Average 200 Days | 6.47 |
| Average Volume | 1.73M |
| Shares Outstanding | 420.48M |
| % Held by Institutions | N/A |
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |